SAN FRANCISCO, CA – A new report from The Wall Street Journal sheds light on the culture of substance use surrounding Elon Musk and his business associates. According to the report, board members and directors of Musk’s companies either engage in or enable his drug use to maintain their proximity to the billionaire, feeling obligated to participate due to financial ties with his companies.
Sources cited in The Journal’s report revealed that Musk has been observed using ketamine and liquid ecstasy at parties in recent years, creating a culture of peer pressure among his closest business associates. The fear of upsetting Musk and the potential impact on their wealth and social status has led to an environment where refusing to use drugs with him is not an option for many of those connected to his companies.
Following The Journal’s report, which detailed Musk’s use of cocaine, LSD, ecstasy, and magic mushrooms, the billionaire responded by indicating that he should “keep doing” whatever he’s been doing. However, concerns have been raised regarding the potential impact of his reported drug use on his company’s government contracts, particularly in the context of federal regulations on drug use.
The implications of Musk’s drug use have also raised concerns within the leadership of his companies, with reports indicating that a former director at Tesla chose not to seek reelection to the company’s board due to concerns about Musk’s drug use and unpredictable behavior. Similarly, executives at SpaceX reportedly expressed concern about Musk’s behavior during a meeting, leading to questions about the impact of his substance use on the functioning of the company.
Overall, The Wall Street Journal’s report paints a picture of a culture of substance use that extends beyond Musk himself, impacting the behavior and decision-making of those connected to his companies. The revelations have sparked discussions about the potential consequences of such a culture within the context of corporate governance and business ethics.